Consolidation with carfilzomib lenalidomide and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism in the absence of bisphosphonates among newly diagnosed patients with multiple myeloma

摘要

Baseline characteristics of included patients (  = 40).